|Bid||36.28 x 2200|
|Ask||42.35 x 1400|
|Day's Range||38.96 - 41.64|
|52 Week Range||26.10 - 129.09|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.70|
Natera, Inc. ( NASDAQ:NTRA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has presented data on the clinical utility of the company's Prospera™ and Renasight™ tests in 14 sessions at the American Transplant Congress (ATC) 2022 meeting. This expands on the thirteen peer-reviewed papers that have been published over the last twelve months, demonstrating the strong performance of both assays.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the 2022 ASCO® Annual Meeting taking place June 3 – 7, 2022.